Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study

Izalontamab was well tolerated and demonstrated preliminary antitumor activity in patients with locally advanced or metastatic epithelial tumors, supporting it as a promising therapeutic candidate for combination therapies, with a phase III study currently underway.

Authors

Institutions

Publication Details

Journal
Clinical Cancer Research
Published
2025-04-21
DOI
https://doi.org/10.1158/1078-0432.ccr-25-0206
Citations
7
Primary Topic
HER2/EGFR in Cancer Research
Type
article
Field-Weighted Citation Impact
7.32

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study

Hongyun Zhao, Yuanyuan Zhao, Jinhui Xue, Wei Hong et al.
7 citations
Clinical Cancer Research
HER2/EGFR in Cancer Research
7.32
article

Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study

Hongyun Zhao, Yuanyuan Zhao, Jinhui Xue, Wei Hong, Shaodong Hong, Yunpeng Yang, Yan Huang, Li Zhang, Yuxiang Ma, Sa Xiao, Wenfeng Fang, Yang Zhang, Hai Zhu, Yongsheng Wang, Qianwen Liu, Yi Zhu
article en
7 citations

Abstract

Izalontamab was well tolerated and demonstrated preliminary antitumor activity in patients with locally advanced or metastatic epithelial tumors, supporting it as a promising therapeutic candidate for combination therapies, with a phase III study currently underway.

Clinical Cancer ResearchVol. 31(21)
Sun Yat-sen University (CN), Sichuan University (CN), West China Hospital of Sichuan University (CN), Zhejiang Cancer Hospital (CN), Buchang Pharma (China) (CN), Cancer Hospital of Chinese Academy of Medical Sciences (CN), Sun Yat-sen University Cancer Center (CN), University of Chinese Academy of Sciences (CN)
National Natural Science Foundation of China, Sun Yat-sen University, Sun Yat-sen University Cancer Center
Good health and well-being
Openalex Percentile: Top 3%
HER2/EGFR in Cancer Research
7.32
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.